...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight Preterm Infants: A Multicenter, Randomized, Controlled Trial
【24h】

Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight Preterm Infants: A Multicenter, Randomized, Controlled Trial

机译:口服益生菌可预防极低出生体重早产儿坏死性小肠结肠炎:一项多中心,随机,对照试验

获取原文
           

摘要

OBJECTIVE. The goal was to investigate the efficacy of orally administered probiotics in preventing necrotizing enterocolitis for very low birth weight preterm infants.METHODS. A prospective, blinded, randomized, multicenter controlled trial was conducted at 7 NICUs in Taiwan, to evaluate the beneficial effects of probiotics in necrotizing enterocolitis among very low birth weight infants (birth weight: 1500 g). Very low birth weight infants who survived to start enteral feeding were eligible and were assigned randomly to 2 groups after parental informed consent was obtained. Infants in the study group were given Bifidobacterium bifidum and Lactobacillus acidophilus , added to breast milk or mixed feeding (breast milk and formula), twice daily for 6 weeks. Infants in the control group were fed with breast milk or mixed feeding. The clinicians caring for the infants were blinded to the group assignment. The primary outcome measurement was death or necrotizing enterocolitis (Bell's stage ≥2).RESULTS. Four hundred thirty-four infants were enrolled, 217 in the study group and 217 in the control group. The incidence of death or necrotizing enterocolitis (stage ≥2) was significantly lower in the study group (4 of 217 infants vs 20 of 217 infants). The incidence of necrotizing enterocolitis (stage ≥2) was lower in the study group, compared with the control group (4 of 217 infants vs 14 of 217 infants). No adverse effect, such as sepsis, flatulence, or diarrhea, was noted.CONCLUSION. Probiotics, in the form of Bifidobacterium and Lactobacillus , fed enterally to very low birth weight preterm infants for 6 weeks reduced the incidence of death or necrotizing enterocolitis.
机译:目的。目的是研究口服益生菌预防极低出生体重早产儿坏死性小肠结肠炎的功效。在台湾的7个新生儿重症监护病房(NICU)进行了一项前瞻性,盲目,随机,多中心对照试验,以评估益生菌对极低出生体重婴儿(出生体重:<1500 g)坏死小肠结肠炎的有益作用。能够开始肠内喂养而存活的极低出生体重婴儿符合条件,并在获得父母知情同意后随机分为两组。在研究组中,给婴儿分叉双歧杆菌和嗜酸乳杆菌,添加到母乳或混合喂养(母乳和配方奶粉)中,每天两次,共6周。对照组婴儿喂养母乳或混合喂养。照顾婴儿的临床医生对小组任务不了解。主要结局指标为死亡或坏死性小肠结肠炎(贝尔阶段≥2)。入选344例婴儿,研究组217例,对照组217例。在研究组中,死亡或坏死性小肠结肠炎(≥2级)的发生率显着降低(217例婴儿中的4例与217例婴儿中的20例)。与对照组相比,研究组坏死性小肠结肠炎(≥2期)的发生率低于对照组(217例婴儿中的4例与217例婴儿中的14例)。未观察到不良反应,如败血症,肠胃气胀或腹泻。益生菌以双歧杆菌和乳杆菌的形式经肠饲喂体重很低的早产儿6周,可降低死亡或坏死性小肠结肠炎的发生率。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号